Heartsciences Inc. cash flow statement

In fiscal 2026, Heartsciences Inc.'s operations generated −$7.4m of cash; it spent $3,554 on capital projects, leaving free cash flow of −$7.4m.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Heartsciences Inc.: cash flow statement, annual
Fiscal year	2022Apr 2022	2023Apr 2023	2024Apr 2024	2025Apr 2025	2026Apr 2026	LTMJul 2026
Cash from operations	−3,644	−5,774	−6,070	−7,413	−7,427	−6,792
Depreciation and amortisation	27	27	28	38	28	27
Stock-based pay	68	248	405	250	1,312	1,877
Capital spending	2	18	64	3	4	0
Free cash flow	−3,646	−5,792	−6,135	−7,416	−7,430	−6,792
Free cash flow after stock pay	−3,714	−6,040	−6,540	−7,666	−8,743	−8,669
Shares issued	—	5,195	—	1,148	173	—

US$ thousands unless shown otherwise. Fiscal quarters.

Heartsciences Inc.: cash flow statement, quarterly
Quarter	2024 Q4Apr 2024	2025 Q3Jan 2025	2025 Q4Apr 2025	2026 Q1Jul 2025	2026 Q2Oct 2025	2026 Q3Jan 2026	2026 Q4Apr 2026	2027 Q1Jul 2026
Cash from operations	−1,577	−1,620	−1,591	−1,953	−2,334	−1,463	−1,677	−1,319
Depreciation and amortisation	9	6	8	7	7	7	7	6
Stock-based pay	78	55	96	175	437	376	325	739
Capital spending	49	0	0	—	—	−9	0	—
Free cash flow	−1,626	−1,620	−1,591	—	—	−1,453	−1,677	—
Free cash flow after stock pay	−1,704	−1,675	−1,687	—	—	−1,829	−2,001	—
Shares issued	—	—	171	0	—	—	0	10

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CUPR vs HSCS HSCS vs POAS HSCS vs PAVM

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Heartsciences Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Heartsciences Inc.